Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,921 to 2,940 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Vaccine vs Placebo: serious adverse events | 77 of 1,253 95 of 1,251 | -1.4 points -3.4 to 0.5 | 2,504 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
| Carotid-Artery Stenting vs Carotid Endarterectomy: serious adverse events | 322 of 1,262 292 of 1,240 | 2.0 points -1.4 to 5.3 | 2,502 | NCT00004732 Carotid Revascularization Endarterectomy Versus Stenting Trial |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 84 of 1,242 103 of 1,260 | -1.4 points -3.5 to 0.7 | 2,502 | NCT02173379 Absorb IV Randomized Controlled Trial |
| ICD Implant Without Defibrillation Testing vs ICD Implant With Defibrillation Testing: First Occurrence of the Composite of Failed First Appropriate Clinical Shock From the Implantable Cardioverter Defibrillator (ICD) or Arrhythmic Death | 90 of 1,247 104 of 1,253 | -1.1 points -3.2 to 1.0 | 2,500 | NCT00800384 Shockless Implant Evaluation |
| ICD Implant Without Defibrillation Testing vs ICD Implant With Defibrillation Testing: serious adverse events | 776 of 1,247 790 of 1,253 | -0.8 points -4.6 to 3.0 | 2,500 | NCT00800384 Shockless Implant Evaluation |
| Intervention vs Control: Proportion of Patients With Intensification of Lipid Lowering Therapy | 159 of 1,130 142 of 1,370 | 3.7 points 1.1 to 6.3 | 2,500 | NCT04394715 Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID) |
| Intervention vs Control: deaths from any cause | 18 of 1,130 29 of 1,370 | -0.5 points -1.6 to 0.6 | 2,500 | NCT04394715 Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID) |
| CVnCoV 12 μg Vaccine vs Placebo: Number of Participants Aged ≥ 61 Who Experienced a First Episode of Virologically-confirmed (RT-PCR Positive) Case of COVID-19 of Any Severity | 12 of 1,319 9 of 1,180 | 0.1 points -0.6 to 0.9 | 2,499 | NCT04652102 A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older |
| Vaccine vs Placebo: Participant Dropout Through Month 48 | 340 of 1,251 436 of 1,245 | -7.8 points -11.4 to -4.2 | 2,496 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
| Vaccine vs Placebo: HIV-1 Infections Diagnosed After Day 0 Including All Available Follow-up Through the Maximum Month 48 Visit | 75 of 1,251 68 of 1,245 | 0.5 points -1.3 to 2.4 | 2,496 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
| Vaccine vs Placebo: Participant Dropout Prior to Unblinding | 99 of 1,251 127 of 1,245 | -2.3 points -4.6 to -0.0 | 2,496 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
| Vaccine vs Placebo: HIV-1 Infections Diagnosed After Day 0 Through the Month 24 Visit | 49 of 1,251 46 of 1,245 | 0.2 points -1.3 to 1.7 | 2,496 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
| Absorb BVS vs XIENCE: Number of Participants With Rehospitalization | 443 of 1,238 446 of 1,254 | 0.2 points -3.5 to 4.0 | 2,492 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 94 of 1,236 72 of 1,255 | 1.9 points -0.1 to 3.9 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 67 of 1,236 38 of 1,255 | 2.4 points 0.8 to 4.0 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 117 of 1,236 89 of 1,255 | 2.4 points 0.2 to 4.6 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 42 of 1,236 38 of 1,255 | 0.4 points -1.0 to 1.8 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 138 of 1,236 107 of 1,255 | 2.6 points 0.3 to 5.0 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 163 of 1,236 139 of 1,255 | 2.1 points -0.5 to 4.7 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 70 of 1,236 38 of 1,255 | 2.6 points 1.0 to 4.3 | 2,491 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=147"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=147
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00865566-sae",
"title": "Vaccine vs Placebo: serious adverse events",
"summary": "77 of 1253 against 95 of 1251; risk difference -1.4 points, 95% interval -3.4 to 0.5; NCT00865566, Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men",
"record": "/library/comparisons/NCT00865566-sae",
"nct_id": "NCT00865566",
"kind": "serious-adverse-events",
"participants": 2504,
"risk_difference": {
"value": -0.014486734634638655,
"lower": -0.034499130922535884,
"upper": 0.0054039186845659705
},
"group_1": "77 of 1,253",
"group_2": "95 of 1,251",
"difference": "-1.4 points",
"interval": "-3.4 to 0.5",
"trial_title": "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men"
},
{
"id": "NCT00004732-sae",
"title": "Carotid-Artery Stenting vs Carotid Endarterectomy: serious adverse events",
"summary": "322 of 1262 against 292 of 1240; risk difference 2.0 points, 95% interval -1.4 to 5.3; NCT00004732, Carotid Revascularization Endarterectomy Versus Stenting Trial",
"record": "/library/comparisons/NCT00004732-sae",
"nct_id": "NCT00004732",
"kind": "serious-adverse-events",
"participants": 2502,
"risk_difference": {
"value": 0.019666683707376953,
"lower": -0.01406800847548393,
"upper": 0.05331700323112988
},
"group_1": "322 of 1,262",
"group_2": "292 of 1,240",
"difference": "2.0 points",
"interval": "-1.4 to 5.3",
"trial_title": "Carotid Revascularization Endarterectomy Versus Stenting Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=148",
"request_id": "lsHnA05EWViroOa2"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant